Treatment goals and quality of life (QOL) in a survey of patients with ER+/HER2-metastatic breast cancer (mBC)

被引：0
|
作者：
Sammons, Sarah L.
Meisel, Jane
Shanahan, Kelly
Pluard, Timothy
Kozlowski, Monica
Carroll, Dominic
Attias, Elizabeth
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P6-09-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-09-01
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Capecitabine (X) improves quality of life (QoL) in patients (pts) with metastatic breast cancer (MBC).
    Segalla, J
    Oliveira, C
    Cabral, S
    Lago, S
    Ribeiro, R
    Perdicaris, M
    Abdo, E
    Garicochea, B
    Moore, F
    Fabiani, C
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S201 - S201
  • [22] Biomarker analysis from a phase I study using gedatolisib plus palbociclib plus hormone therapy in ER+/HER2-metastatic breast cancer (mBC).
    Wesolowski, Robert
    Pathan, Nuzhat
    Zhu, Zhou
    Stringer-Reasor, Erica Michelle
    Han, Hyo S.
    Dees, Elizabeth Claire
    Bardia, Aditya
    Layman, Rachel M.
    Weise, Amy
    Kabos, Peter
    Lu, Janice M.
    Kern, Kenneth Alan
    Pierce, Kristen J.
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] Impact of adding palbociclib to letrozole on pain severity and pain interference with various activities of daily life in patients with ER+, HER2-metastatic breast cancer as first line treatment
    Bell, Timothy
    Crown, John Paul
    Lang, Istvan
    Bhattacharyya, Helen
    Zanotti, Giovanni
    Randolph, Sophia
    Kim, Sindy
    Huang, Xin
    Bartlett, Cynthia Huang
    Finn, Richard
    Slamon, Dennis
    CANCER RESEARCH, 2015, 75
  • [24] PATIENT CHARACTERISTICS AND TREATMENT PATTERNS IN ER+/HER2-METASTATIC BREAST CANCER IN THE UK: RESULTS FROM A RETROSPECTIVE MEDICAL RECORD REVIEW
    Kurosky, S.
    Mitra, D.
    Zanotti, G.
    Kaye, J. A.
    VALUE IN HEALTH, 2015, 18 (07) : A492 - A492
  • [25] VAGINAL/VULVAR SYMPTOMS WITH LASOFOXIFENE VERSUS FULVESTRANT IN ESR1-MUTATED, ER+/HER2-METASTATIC BREAST CANCER PATIENTS
    Goldfarb, S. B.
    Sammons, S. L.
    Meisel, J. L.
    Pluard, T. J.
    Jenkins, S. N.
    Komm, B.
    Carroll, D.
    Portman, D. J.
    JOURNAL OF SEXUAL MEDICINE, 2023, 20
  • [26] Using real-world data to evaluate the performance of endocrine therapies in ER+/Her2-metastatic breast cancer patients.
    Chen, Tenghui
    Zhang, Zhaojie
    Gao, Lei
    Scholz, Catherine
    Gualberto, Antonio
    Yu, Lihua
    Yu, Kun
    CANCER RESEARCH, 2022, 82 (12)
  • [27] Physician survey in the treatment of HR+/HER2-metastatic breast cancer in Egypt
    Aboelkheir, E.
    Ashour, A.
    Fadel, S.
    Arafat, W.
    BREAST, 2021, 56 : S31 - S31
  • [28] Tumor-agnostic measurement of ctDNA levels in first line ER+, HER2-metastatic breast cancer patients as a marker for survival
    Verschoor, Noortje
    Kraan, Jaco
    de Weerd, Vanja
    Van, Ngoc M.
    Jager, Agnes
    Sleijfer, Stefan
    Martens, John Wm
    Wilting, Saskia M.
    CANCER RESEARCH, 2023, 83 (05)
  • [29] Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2-metastatic breast cancer (mBC).
    Bardia, Aditya
    Linden, Hannah M.
    Ulaner, Gary A.
    Chandarlapaty, Sarat
    Gosselin, Alice
    Doroumian, Severine
    Celanovic, Marina
    Campone, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Time-to-failure in 1st-line endocrine therapy with ER+/HER2-metastatic breast cancer
    Nishimura, S.
    Akiyoshi, S.
    Koga, C.
    Oikawa, M.
    Nskamura, Y.
    Ishida, M.
    Ohno, S.
    BREAST, 2015, 24 : S82 - S83
12345